AcuCort (ACUC) Q3 2026 earnings summary

Executive summary

• Zeqmelit® is approved and launched in Sweden, Denmark, Norway and Finland; Glenmark plans launches in six European markets during 2027.

• Priorities include a Q4 2026 US FDA NDA submission, additional distribution or licensing agreements, and commercial expansion with Glenmark Pharmaceuticals.

Financial highlights

• Q3 revenue was 72 kSEK versus 517 kSEK YoY; 9M revenue was 1,230 kSEK versus 679 kSEK.

• Q3 net loss was 7,542 kSEK versus 5,340 kSEK; 9M net loss was 22,576 kSEK versus 19,433 kSEK.

• Q3 operating loss was 7.578m SEK versus 5.333m; 9M operating loss was 22.648m versus 19.655m.

• Cash and bank at Sep. 30 was 6.515m SEK, down from 27.012m at Dec. 31, 2025.

• Q3 EPS was -SEK 0.03 versus -SEK 0.02; 9M EPS was -SEK 0.06 versus -SEK 0.08, basic and diluted.

Outlook and guidance

• Target is to submit the US NDA in Q4 2026; the FDA renewed the Small Business Waiver and an iPSP agreement is in place.

• Glenmark plans 2027 launches in Germany, the Netherlands, Czechia, Austria, Slovakia and Ukraine; launch preparations are underway.

• Roadmap includes US FDA approval and launch, launches in Germany and five additional countries, and positive cash flow for a full quarter by 2028.

• Six 2026 conferences generated more than 100 business contacts, over 40 active dialogues and 20 confidentiality agreements, spanning the EU, North America and the Middle East.